<DOC>
	<DOC>NCT03100591</DOC>
	<brief_summary>The primary purpose of this study is to investigate the rate and routes (urine and feces) of elimination of ACT-132577, and the mass balance in urine and feces</brief_summary>
	<brief_title>A Study to Evaluate ACT-132577 in Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Signed informed consent in a language understandable to the subject prior to any studymandated procedure; Healthy male subjects aged between 45 and 65 years (inclusive) at screening; Body mass index of 18.0 to 28.0 kg/m2 (inclusive) at screening; Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests. Values of hepatic aminotransferase (alanine aminotransferase and/or aspartate aminotransferase) &gt; 3 × upper limit of normal range at screening; Hemoglobin &lt; 100 g/L at screening; Known hypersensitivity to ACT132577 or drugs of the same class, or any excipient of the ACT132577 drug formulation; Known hypersensitivity or allergy to natural rubber latex; Previous exposure to ACT132577; Treatment with another investigational drug within 3 months prior to screening or participation in more than 4 investigational drug studies within 1 year prior to screening; Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol; A radiation burden of &gt; 0.1 milliSievert (mSv) and ≤ 1.0 mSv in the period of 1 year prior to screening; a radiation burden of ≥ 1.1 mSv and ≤ 2.0 mSv in the period of 2 years prior to screening, etc. (add 1 year per 1 mSv).</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>